ANB Bank Has $3.12 Million Stock Position in Stryker Corporation $SYK

ANB Bank lowered its position in Stryker Corporation (NYSE:SYK) by 15.2% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,896 shares of the medical technology company’s stock after selling 1,413 shares during the period. Stryker comprises 1.4% of ANB Bank’s holdings, making the stock its 18th largest position. ANB Bank’s holdings in Stryker were worth $3,124,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its position in shares of Stryker by 1.1% during the first quarter. Vanguard Group Inc. now owns 33,059,964 shares of the medical technology company’s stock worth $12,306,572,000 after purchasing an additional 361,136 shares during the period. Price T Rowe Associates Inc. MD increased its stake in Stryker by 9.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 12,131,218 shares of the medical technology company’s stock worth $4,515,847,000 after purchasing an additional 1,021,496 shares in the last quarter. Geode Capital Management LLC raised its holdings in Stryker by 1.1% during the 2nd quarter. Geode Capital Management LLC now owns 7,393,611 shares of the medical technology company’s stock worth $2,910,445,000 after buying an additional 79,654 shares during the period. Goldman Sachs Group Inc. lifted its stake in Stryker by 13.1% in the first quarter. Goldman Sachs Group Inc. now owns 2,252,895 shares of the medical technology company’s stock valued at $838,640,000 after buying an additional 261,058 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Stryker by 4.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,086,960 shares of the medical technology company’s stock valued at $776,871,000 after buying an additional 83,954 shares during the period. 77.09% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently commented on SYK. Rothschild & Co Redburn started coverage on shares of Stryker in a report on Thursday, September 18th. They set a “neutral” rating and a $420.00 price objective on the stock. Rothschild Redb upgraded Stryker to a “hold” rating in a report on Thursday, September 18th. Royal Bank Of Canada restated an “outperform” rating and issued a $435.00 price target on shares of Stryker in a report on Friday. UBS Group set a $408.00 price objective on Stryker in a research report on Monday, October 13th. Finally, Sanford C. Bernstein reiterated an “outperform” rating on shares of Stryker in a report on Monday, November 3rd. Thirteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, Stryker currently has an average rating of “Moderate Buy” and a consensus target price of $434.37.

Insider Buying and Selling

In other news, Director Ronda E. Stryker sold 276,173 shares of the company’s stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $353.28, for a total transaction of $97,566,397.44. Following the sale, the director owned 2,702,108 shares in the company, valued at $954,600,714.24. This represents a 9.27% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Viju Menon sold 500 shares of the firm’s stock in a transaction on Monday, August 25th. The shares were sold at an average price of $390.61, for a total transaction of $195,305.00. Following the completion of the transaction, the insider directly owned 12,511 shares of the company’s stock, valued at $4,886,921.71. This represents a 3.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 520,500 shares of company stock worth $184,803,065. Company insiders own 5.90% of the company’s stock.

Stryker Trading Down 3.0%

Stryker stock opened at $362.39 on Friday. The company has a market cap of $138.59 billion, a price-to-earnings ratio of 48.00, a P/E/G ratio of 2.66 and a beta of 0.94. The firm has a 50-day moving average of $371.96 and a 200-day moving average of $381.22. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06. Stryker Corporation has a one year low of $329.16 and a one year high of $406.19.

Stryker (NYSE:SYK) last released its earnings results on Thursday, October 30th. The medical technology company reported $3.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.13 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The business had revenue of $6.06 billion for the quarter, compared to the consensus estimate of $6.04 billion. During the same quarter in the previous year, the business earned $2.87 earnings per share. Stryker’s quarterly revenue was up 10.2% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. On average, equities analysts expect that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.